To explore the genetic basis of the ABO blood group and its links to disease risk, progression, and drug response, without implying clinical implications.
Approach:
Key Findings:
Polymorphisms in the ABO gene influence susceptibility to various diseases, including cancers and cardiovascular diseases.
Non-O blood groups are linked to higher concentrations of von Willebrand factor (vWF), increasing the risk of atherosclerosis and thrombosis.
Individuals with blood type O are more susceptible to gastrointestinal infections, such as those caused by Helicobacter pylori.
ABO blood group affects drug efficacy, with type O individuals requiring lower doses of warfarin and showing variable responses to other medications.
Interpretation:
The ABO blood group system plays a role in disease pathogenesis and treatment responses.
Limitations:
The review primarily focuses on studies published in English, which may limit the generalizability of the findings.
Exclusion of animal or cellular studies may limit the understanding of underlying mechanisms.
Conclusion:
The findings suggest that ABO blood typing could be relevant for risk assessment and therapeutic strategies, but further research is needed to support clinical integration.
